

Adamas Pharmaceuticals Inc  
Form SC 13G  
June 01, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No.)\*

Adamas Pharmaceuticals, Inc.  
(Name of Issuer)

Common Stock, \$0.001 par value per share  
(Title of Class of Securities)

00548A106  
(CUSIP Number)

May 22, 2017  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

CUSIP  
No 00548A106

1. NAME OF  
REPORTING  
PERSONS  
I.R.S.  
IDENTIFICATION  
NOS. OF  
ABOVE  
PERSONS  
(ENTITIES  
ONLY)

Armistice  
Capital,  
LLC

2. CHECK THE  
APPROPRIATE  
BOX IF A  
MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)  
(a)   
(b)

3. SEC USE  
ONLY

4. CITIZENSHIP  
OR PLACE  
OF  
ORGANIZATION

Delaware

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON WITH

5. SOLE  
VOTING  
POWER

0

SHARED  
6. VOTING  
POWER

1,144,000

SOLE  
7. DISPOSITIVE  
POWER

0

SHARED  
8. DISPOSITIVE  
POWER

1,144,000

AGGREGATE  
AMOUNT  
9. BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

1,144,000

CHECK  
BOX IF  
THE  
AGGREGATE  
AMOUNT  
10. IN ROW (9)  
EXCLUDES  
CERTAIN  
SHARES  
(SEE  
INSTRUCTIONS)

PERCENT  
OF CLASS  
REPRESENTED  
11. BY  
AMOUNT  
IN ROW (9)

5.12%

12.

TYPE OF  
REPORTING  
PERSON  
(SEE  
INSTRUCTIONS)

IA, OO

---

CUSIP  
No 00548A106

1. NAME OF REPORTING PERSONS  
I.R.S. IDENTIFICATION NOS. OF ABOVE  
PERSONS (ENTITIES ONLY)

Armistice Capital Master Fund Ltd.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE  
INSTRUCTIONS)

(a)

(b)

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON  
WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

1,144,000

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

1,144,000

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING  
PERSON

1,144,000

- CHECK BOX IF THE AGGREGATE AMOUNT IN  
10. ROW (9) EXCLUDES CERTAIN SHARES (SEE  
INSTRUCTIONS)

11. PERCENT OF CLASS REPRESENTED BY  
AMOUNT IN ROW (9)

5.12%

12. TYPE OF REPORTING PERSON (SEE  
INSTRUCTIONS)

CO

---

CUSIP  
No 00548A106

- NAME OF  
1. REPORTING  
PERSONS  
I.R.S.  
IDENTIFICATION  
NOS. OF  
ABOVE  
PERSONS  
(ENTITIES  
ONLY)

Steven Boyd

- CHECK THE  
APPROPRIATE  
BOX IF A  
2. MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)  
(a)   
(b)

3. SEC USE  
ONLY

- CITIZENSHIP  
4. OR PLACE  
OF  
ORGANIZATION

United  
States of  
America

- NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON WITH

- SOLE  
5. VOTING  
POWER

0

SHARED

6. VOTING  
POWER

1,144,000

SOLE

7. DISPOSITIVE  
POWER

0

SHARED

8. DISPOSITIVE  
POWER

1,144,000

AGGREGATE  
AMOUNT

9. BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

1,144,000

CHECK

BOX IF

THE

AGGREGATE

AMOUNT

10. IN ROW (9)

EXCLUDES

CERTAIN

SHARES

(SEE

INSTRUCTIONS)

PERCENT

OF CLASS

REPRESENTED

11. BY

AMOUNT

IN ROW (9)

5.12%



TYPE OF  
REPORTING  
12.PERSON  
(SEE  
INSTRUCTIONS)

IN, HC

---

CUSIP No 00548A106

Item 1. (a). Name of Issuer:

Adamas  
Pharmaceuticals,  
Inc.

(b). Address of  
Issuer's Principal  
Executive  
Offices:

1900 Powell  
Street, Suite 750  
Emeryville,  
California 94608  
United States of  
America

Item 2. (a). Name of Person  
Filing:

Armistice  
Capital, LLC  
Armistice Capital  
Master Fund Ltd.  
Steven Boyd

(b). Address of  
Principal  
Business Office,  
or if None,  
Residence:

Armistice  
Capital, LLC  
510 Madison  
Avenue, 22nd  
Floor  
New York, New  
York 10022  
United States of  
America

Armistice Capital  
Master Fund Ltd.  
c/o dms  
Corporate

Services Ltd.  
20 Genesis Close  
P.O. Box 314  
Grand Cayman  
KY1-1104  
Cayman Islands

Steven Boyd  
c/o Armistice  
Capital, LLC  
510 Madison  
Avenue, 22nd  
Floor  
New York, New  
York 10022  
United States of  
America

(c) Citizenship:

Armistice  
Capital, LLC –  
Delaware  
Armistice Capital  
Master Fund Ltd.  
– Cayman Islands  
Steven Boyd –  
United States of  
America

(d) Title of Class of  
Securities:

Common Stock,  
\$0.001 par value  
per share

(e) CUSIP Number:

00548A106

---

Edgar Filing: Adamas Pharmaceuticals Inc - Form SC 13G

Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

- (a)  Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
  - (b)  Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
  - (c)  Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
  - (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  - (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  - (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
  - (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
  - (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
  - (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  - (j)  Group, in accordance with s.240.13d-1(b)(1)(ii)(J).
-

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Armistice Capital, LLC – 1,144,000  
Armistice Capital Master Fund Ltd. – 1,144,000  
Steven Boyd – 1,144,000

(b) Percent of class:

Armistice Capital, LLC – 5.12%  
Armistice Capital Master Fund Ltd. – 5.12%  
Steven Boyd – 5.12%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

Armistice Capital, LLC – 0  
Armistice Capital Master Fund Ltd. – 0  
Steven Boyd – 0

(ii) Shared power to vote or to direct the vote

Armistice Capital, LLC – 1,144,000  
Armistice Capital Master Fund Ltd. – 1,144,000  
Steven Boyd – 1,144,000

(iii) Sole power to dispose or to direct the disposition of

Armistice Capital, LLC – 0  
Armistice Capital Master Fund Ltd. – 0  
Steven Boyd – 0

(iv) Shared power to dispose or to direct the disposition of

Armistice Capital, LLC – 1,144,000  
Armistice Capital Master Fund Ltd. – 1,144,000  
Steven Boyd – 1,144,000

---

Item  
5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

N/A

Item  
6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item  
7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item  
8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item  
9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item  
10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11..

---

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

June 1, 2017  
(Date)

Armistice Capital, LLC\*

By: /s/ Steven Boyd  
Steven Boyd  
Managing Member

Armistice Capital Master Fund Ltd.

By: /s/ Steven Boyd  
Steven Boyd  
Director

/s/ Steven Boyd\*  
Steven Boyd

\* This Reporting Person disclaims beneficial ownership in the Common Stock, except to the extent of his or its pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

---



Exhibit A

AGREEMENT

The undersigned agree that this Schedule 13G dated June 1, 2017 relating to the Common Stock, \$0.001 par value per share, of Adamas Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

Armistice Capital, LLC

By: /s/ Steven Boyd  
Steven Boyd  
Managing Member

Armistice Capital Master Fund Ltd.

By: /s/ Steven Boyd  
Steven Boyd  
Director

/s/ Steven Boyd  
Steven Boyd

SK 27622 0002 7505878